Toxicogenomics applied to predictive and exploratory toxicology for the safety assessment of new chemical entities: A long road with deep potholes

Progress in Drug Research

Volumn 64, Issue , 2007, Pages 217-238

  Pognan, François ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; ANTIVIRUS AGENT; CHLORAMPHENICOL; LINEZOLID; MESSENGER RNA; OXAZOLIDINONE DERIVATIVE; PARACETAMOL;

ANEMIA; DATA BASE; DOSE RESPONSE; DRUG INDUSTRY; DRUG MECHANISM; DRUG TARGETING; ERYTHROPENIA; GENE ACTIVITY; GENE EXPRESSION PROFILING; GENOME; GENOMICS; HUMAN; LIPIDOSIS; LIVER FAILURE; LIVER TOXICITY; NONHUMAN; PREDICTION; PRINCIPAL COMPONENT ANALYSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; RISK ASSESSMENT; ANIMAL; METHODOLOGY; SAFETY; TOXICITY TESTING; TOXICOGENETICS;

ANIMALS; ANTI-INFECTIVE AGENTS; HUMANS; SAFETY; TOXICITY TESTS; TOXICOGENETICS;

EID: 33846903587     PISSN: 0071786X     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-7643-7567-6_9     Document Type: Review

References (54)

1. Colebatch G, Trevaskis B, Udvardi M (2002) Functional genomics: Tools of the trade. New Phytol 153: 27-36
2. Mahler SM, Chin DY, Van Dyk DD (2003) The application of emerging technologies in genomics and proteomics to drug development. J Pharm Pract Res 33: 7-11
3. van Hall NL, Vorst O, van Houwelingen AM, Kok EJ, Peijnenburg A, Aharoni A, van Tunen AJ, Keijer J (2000) The application of DNA microarray in gene expression analysis. J Biotechnol 78: 271-280
4. Butte A (2002) The use and analysis of microarray data. Nat Rev Drug Disc 1: 951-960
5. Nicholson JK, Wilson ID (2003) Understanding 'global' systems biology: metabonomics and the continuum of metabolism. Nat Rev Drug Discov 2: 668-676
6. De Longueville F, Bertholet V, Remacle J (2004) DNA microarrays as a tool in toxicogenomics. Comb Chem High Throughput Screening 7: 207-211
7. Witkampt RF (2005) Genomics and system biology - how relevant are the developments to veterinary pharmacology, toxicology and therapeutics? J Vet Pharmacol Therap 28: 235-245
8. Loferer H, Jacobi A, Posch A, Gauss C, Meier-Ewert S, Seizinger B (2000) Integrated bacterial genomics for the discovery of novel antimicrobials. Drug Discovery Today 5: 107-114
9. Tugwood JD, Hollins LE, Cockerill MJ (2003) Genomics and the search for novel biomarkers in toxicology. Biomarkers 8: 79-92
10. Kramer JA, Kolaja K (2002) Toxicogenomics: an opportunity to optimise drug development and safety evaluation. Expert Opin Drug Saf 1: 275-286
11. Wildsmith S, Spence F (2003) Preparation and utilisation of microarrays. In: ME Burczynski (ed): An introduction to toxicogenomics. CRC Press, Boca Raton, USA, pp 3-16
12. Li J, Johnson JA (2003) Comparative studies using cDNA vs. oligonucleotide arrays. In: ME Burczynski (ed): An introduction to toxicogenomics. CRC Press, Boca Raton, USA. pp 17-27
13. Sebastiani P, Gussoni E, Kohane IS, Ramoni MF (2003) Statistical challenges in functional genomics. Stat Sci 18: 33-60
14. Ge H, Walhout AJ, Vidal M (2003) Integrating 'omic' information: a bridge between genomics and systems biology. Trends Genet 19: 551-560
15. Guerreiro N, Staedtler F, Grenet O, Kehren J, Chibout S-D (2003) Toxicogenomics in drug development. Toxicol Pathol 31: 471-479
16. Pognan F (2004) Genomics, proteomics andmetabonomics in toxicology: Hopefully not 'fashionomics'. Pharmacogenomics 5: 879-893
17. Muckter H (2003) What is toxicology and how does it occur? Baillieres Best Pract Res Clin Anaes 17: 5-27
18. Chan VSW, Theilade MD (2005) The use of toxicogenomic data in risk assessment: A regulatory perspective. Clin Toxicol 43: 121-126
19. Scheel J, von Brevern M-C, Storck T (2003) An overview of mechanistic toxicogenomics studies. In: ME Burczynski (ed): An introduction to toxicogenomics. CRC Press, Boca Raton, USA. pp 183-209
20. Fountoulakis M, Berndt P, Boelsterli UA, Crameri F, Winter M, Albertini S, Suter L (2000) Two-dimensional database of mouse liver proteins: Changes in hepatic protein levels following treatment with acetaminophen or its nontoxic regioisomer 3-acetamidophenol. Electrophoresis 21: 2148-2161
21. Reilly TP, Bourdi M, Brady JN, Pise-Masison CA, Radonovich MF, George JW, Pohl LR (2001) Expression profiling of acetaminophen liver toxicity in mice using microarray technology. Biochem Biophys Res Com 282: 321-328
22. Ruepp SU, Tonge RP, Shaw J, Wallis N, Pognan F (2002) Genomics and proteomics analysis of acetaminophen toxicity in mouse liver. Toxicol Sci 65: 135-150
23. Coen M, Lenz EM, Nicholson JK, Wilson ID, Pognan F, Lindon JC (2003). An integrated metabonomic investigation of acetaminophen toxicity in the mouse using NMR spectroscopy. Chem Res Tox 16: 295-303
24. Coen M, Ruepp SU, Lindon JC, Nicholson JK, Pognan F, Lenz EM, Wilson ID (2004) Application of transcriptomics and metabonomics yields new insight into the toxicity due to paracetamol in the mouse. J Pharm Biomed Anal 35: 93-105
25. Milano J, McKay J, Dagenais C, Foster-Brown L, Pognan F, Gadient R, Jacobs RT, Zacco A, Greenberg B, Ciaccio PJ (2004) Modulation of notch processing by gamma-secretase inhibitors causes intestinal goblet cell metaplasia and induction of genes known to specify gut secretory lineage differentiation. Toxicol Sci 82: 341-358
26. Cornwell PD, de Souza AT, Ulrich RG (2004) Profiling of hepatic gene expression in rats treated with fibric acid analogs. Mut Res 549: 131-145
27. Peters JM, Cattley RC, Gonzalez FJ (1997) Role of PPAR alpha in the mechanism of action of the nongenotoxic carcinogen and peroxisome proliferator Wy-14,643. Carcinogenesis 18: 2029-2033
28. Montenez JP, Van Bambeke F, Piret J, Brasseur R, Tulkens PM, Mingeot-Leclercq MP (1999) Interactions of macrolide antibiotics (Erythromycin A, roxithromycin, erythromycylamine [Dirithromycin], and azithromycin) with phospholipids: computer-aided conformational analysis and studies on acellular and cell culture models. Toxicol Appl Pharmacol 156: 129-140
29. Casartelli A, Bonato M, Cristofori P, Crivellente F, Dal Negro G, Masotto I, Mutinelli C, Valko K, Bonfante V (2003) A cell-based approach for the early assessment of the phospholipidogenic potential in pharmaceutical research and drug development. Cell Biol Toxicol 19: 161-176
30. Morelli JK, Buehrle M, Pognan F, Barone L, Fieles W, Ciaccio PJ (2006) Validation of an in vitro screen for phopholipidosis using a high content biology platform. Cell Biol Toxicol 22: 15-27
31. Sawada H, Takami K, Asahi SA (2005) Toxicogenomic approach to drug-induced phospholipidosis: Analysis of its induction mechanism and establishment of a novel in vitro screening system. Tox Sci 83: 282-292
32. Suter L, Babiss LE, Wheeldon EB (2004) Toxicogenomics in predictive toxicology drug development. Chem Biol 11: 161-171
33. Porter MW, Castle AL, Orr MS, Mendrick DL (2003) Predictive toxicogenomics. In: ME Burczynski (ed): An introduction to toxicogenomics. CRC Press, Boca Raton, USA. pp 183-209
34. Sherlock G (2000) Analysis of large-scale gene expression data. Curr Opin Immunol 12: 201-205
35. Joliffe IT, Morgan BJ (1992) Principal component analysis and exploratory factor analysis. Stat Methods Med Res 1: 69-95
36. Waring JF, Jolly RA, Ciurlionis R, Lum PY, Praestgaard JT, Morfitt DC, Buratto B, Roberts C, Schadt E, Ulrich RG (2001) Clustering of hepatotoxins based on mechanism of toxicity using gene expression profiles. Toxicol Appl Pharmacol 175: 28-42
37. Mattes WB, Pettit SD, Sansone S-A, Bushel PR, Waters MD (2004) Database development in toxicogenomics: Issues and efforts. Environ Health Perspect 112: 495-505
38. Hayes KR, Vollrath AL, Zastrow GM, McMillan BJ, Craven M, Jovanovich S, Rank DR, Penn S, Walisser JA, Reddy JK et al (2005) EDGE: A centralized resource for the comparison, analysis, and distribution of toxicogenomic information. Mol Pharmacol 67: 1360-1368
39. Huby R, Tugwood JD (2005) Gene expression profiling for pharmaceutical safety assessment. Expert Opin Drug Metab Toxicol 1: 247-260
40. Klaassen CD (ed) (2001) Casarett and Doull's toxicology: the basic science of poisons. Sixth Edition. McGraw-Hill, New York, USA
41. Luhe A, Suter L, Ruepp S, Singer T, Weiser T, Albertini S (2005) Toxicogenomics in the pharmaceutical industry: Hollow promises or real benefit? Mut Res 575: 102-115
42. Olson H, Betton G, Robinson D, Thomas K, Monro A, Kolaja G, Lilly P, Sanders J, Sipes G, Bracken W et al (2000) Concordance of the toxicity of pharmaceuticals in humans and in animals. Regul Toxicol Pharmacol 32: 56-67
43. Bollard ME, Holmes E, Lindon JC, Mitchell SC, Branstetter D, Zhang W, Nicholson JK (2001) Investigations into biochemical changes due to diurnal variation and estrus cycle in female rats using high-resolution (1)H NMR spectroscopy of urine and pattern recognition. Anal Biochem 295: 194-202
44. Wang Y, Tang H, Nicholson JK, Hylands PJ, Sampson J, Holmes E (2005) A metabonomic strategy for the detection of the metabolic effects of chamomile (Matricaria recutita L.) ingestion. J Agric Food Chem 53: 191-196
45. Boess F, Kamber M, Romer S, Gasser R, Muller D, Albertini S, Suter L (2003) Gene expression in two hepatic cell lines, cultured primary hepatocytes, and liver slices compared to the in vivo liver gene expression in rats: possible implications for toxicogenomics use of in vitro systems. Toxicol Sci 73: 386-402
46. Kier LD, Neft R, Tang L, Suizu R, Cook T, Onsurez K, Tiegler K, Sakai Y, Ortiz M, Nolan T et al (2004) Applications of microarrays with toxicologically relevant genes (tox genes) for the evaluation of chemical toxicants in Sprague Dawley rats in vivo and human hepatocytes in vitro. Mutat Res 549: 101-113
47. de Backer MD, van Dijck P (2003) Progress in functional genomics approaches to antifungal drug target discovery. Trends in Microbiol 11: 470-478
48. Parkinson T (2002) The impact of genomics on anti-infectives drugs discovery and development. Trends in Microbiol 10: S22-26
49. Contreras A, Barbacid M, Vazquez D (1974) Binding to ribosomes and mode of action of chloramphenicol analogues. Biochim Biophys Acta 349: 376-388
50. Matassova NB, Rodnina MV, Endermann R, Kroll HP, Pleiss U, Wild H, Wintermeyer W (1999) Ribosomal RNA is the target for oxazolidinones, a novel class of translational inhibitors. RNA 5: 939-946
51. Turton JA, Yallop D, Andrews CM, Fagg R, York M, Williams TC (1999) Haemotoxicity of chloramphenicol succinate in the CD-1 mouse and Wistar Hanover rat. Hum Exp Toxicol 18: 566-576
52. Gerson SL, Kaplan SL, Bruss JB, Le V, Arellano FM, Hafkin B, Kuter DJ. (2002) Hematologic effects of linezolid: summary of clinical experience. Antimicrob Agents Chemother 46: 2723-2726
53. Xu J, Gordon JI (2003) Honor thy symbionts. Proc Natl Acad Sci USA 100: 10452-10459
54. Nicholson JK, Holmes E, Wilson ID (2005) Gut microorganisms, mammalian metabolism and personalized health care. Nat Rev Microbiol 3: 431-438